Trial record 1 of 1 for:    TCD12012
Previous Study | Return to List | Next Study

Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Subjects With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2014 by Sanofi
Sponsor:
Information provided by (Responsible Party):
Sanofi
ClinicalTrials.gov Identifier:
NCT01410513
First received: July 26, 2011
Last updated: July 22, 2014
Last verified: July 2014

July 26, 2011
July 22, 2014
December 2011
July 2014   (final data collection date for primary outcome measure)
Identification Of Dose-Limiting Toxicity (DLT) and Maximum Tolerated Dose (MTD) [ Time Frame: 4 weeks to 8 weeks ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT01410513 on ClinicalTrials.gov Archive Site
  • Number of subjects with treatment emergent adverse events [ Time Frame: Time from receiving first dose of SAR245409 until 30 days after the last dose ] [ Designated as safety issue: No ]
  • Pharmacokinetics (Cmax) of SAR245409 [ Time Frame: up to 2 months ] [ Designated as safety issue: No ]
  • Pharmacokinetics (tmax) of SAR245409 [ Time Frame: up to 2 months ] [ Designated as safety issue: No ]
  • Pharmacokinetics (AUC0-12h) of SAR245409 [ Time Frame: up to 2 months ] [ Designated as safety issue: No ]
  • Pharmacokinetics (Ctrough) of SAR245409 [ Time Frame: up to 2 months ] [ Designated as safety issue: No ]
  • Pharmacokinetics (AUC) of bendamustine [ Time Frame: up to 2 months ] [ Designated as safety issue: No ]
  • Pharmacokinetics (AUClast) of bendamustine [ Time Frame: up to 2 months ] [ Designated as safety issue: No ]
  • Pharmacokinetics (Ceoi) of bendamustine [ Time Frame: up to 2 months ] [ Designated as safety issue: No ]
  • Pharmacokinetics (tmax) of bendamustine [ Time Frame: up to 2 months ] [ Designated as safety issue: No ]
  • Pharmacokinetics (Cl) of bendamustine [ Time Frame: up to 2 months ] [ Designated as safety issue: No ]
  • Pharmacokinetics (Vss) of bendamustine [ Time Frame: up to 2 months ] [ Designated as safety issue: No ]
  • Pharmacokinetics (AUC0-7h) of rituximab [ Time Frame: up to 2 months ] [ Designated as safety issue: No ]
  • Pharmacokinetics (Ceoi) of rituximab [ Time Frame: up to 2 months ] [ Designated as safety issue: No ]
  • Pharmacokinetics (tmax) of rituximab [ Time Frame: up to 2 months ] [ Designated as safety issue: No ]
  • Efficacy as determined by objective response rate (ORR) [ Time Frame: up to 4 years ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Subjects With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia
A Phase 1b, Multicenter, Open-Label, Dose Escalation Study of SAR245409 to Evaluate the Safety, Tolerability and Clinical Activity of SAR245409 in Combination With Rituximab or Bendamustine Plus Rituximab in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

Primary Objective:

- To determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) for SAR245409 when administered in combination with rituximab or bendamustine plus rituximab

Secondary Objectives:

  • To determine the safety and tolerability of SAR245409 in combination with rituximab or bendamustine plus rituximab in subjects with indolent Hon-Hodgkin Lymphoma (iNHL) Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL)
  • To determine the pharmacokinetics (PK) of SAR245409, bendamustine and rituximab when used in combination in subjects with iNHL, MCL or CLL
  • To determine the pharmacodynamic (PD) effects of SAR245409 in combination with rituximab or bendamustine plus rituximab in subjects with iNHL, MCL or CLL
  • To determine the antitumor activity of SAR245409 in combination with rituximab or bendamustine plus rituximab in subjects with iNHL, MCL or CLL

All subjects will take SAR245409 twice daily. All subjects will receive SAR245409 as long as there is clinical benefit.

Combination therapy with SAR245409, bendamustine and rituximab , will be administered over a 28 day cycle for up to 6 to 8 cycles.

Subjects receiving the doublet combination , SAR245409 plus rituximab will receive weekly rituximab for 4 - 8 weeks. Monthly Rituximab may be continued beyond 8 weeks.

Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Indolent Non-Hodgkin Lymphoma
  • Mantle Cell Lymphoma
  • Chronic Lymphocytic Leukemia
Drug: SAR245409
Pharmaceutical form:capsule Route of administration: oral
  • Experimental: SAR245409 + rituximab
    Subjects will receive oral SAR245409 twice daily continuously and weekly rituximab intravenously
    Intervention: Drug: SAR245409
  • Experimental: SAR245409 + rituximab + bendamustine (iNHL, MCL)
    Subjects will receive oral SAR245409 twice daily continuously and monthly bendamustine intravenously.
    Intervention: Drug: SAR245409
  • Experimental: SAR245409 + rituximab+ bendamustine (CLL)
    Subjects will receive oral SAR245409 twice daily continuously and monthly bendamustine and rituximab intravenously
    Intervention: Drug: SAR245409
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
85
July 2014
July 2014   (final data collection date for primary outcome measure)

Inclusion criteria:

  • A confirmed diagnosis of indolent non-Hodgkin lymphoma, mantle cell lymphoma or chronic lymphocytic leukemia
  • Evaluable disease or measurable disease
  • Transfusion independent
  • Able to take oral medication
  • Male and Female subjects > 18 years
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
  • Women of childbearing potential using adequate contraception

Exclusion criteria:

  • Prior therapy with a PI3K, mTOR or dual PI3K/mTOR inhibitor resulting in adverse events necessitating treatment discontinuation
  • Eligible for a hematopoietic stem cell transplant (HSCT)
  • The subject has received investigational or non-investigational cytotoxic chemotherapy (i.e., cyclophosphamide), small molecule cancer therapy (i.e., imatinib), biologic cancer therapies other than rituximab (i.e., alemtuzumab, cytokines, vaccines or other monoclonal antibodies) hormonal therapy, radio- or immuno- conjugates (e.g. ibritumomab tiuxetan, tositumomab) or immunosuppressants to treat malignancy within 4 weeks prior to Cycle 1, Day 1
  • Radiation therapy within 2 weeks prior to Cycle 1, Day 1
  • Autologous Hematopoietic Stem Cell Transplant (HSCT) within the past 16 weeks
  • Prior allogeneic HSCT
  • Active central nervous system (CNS) metastases or leptomeningeal involvement
  • Positive Hepatitis B surface antigen (HBsAg) or Hepatitis C Antibody (anti-HCV)
  • Hereditary or acquired immunodeficiency syndrome or human immunodeficiency virus (HIV) infection
  • Active peptic ulcer disease requiring treatment with proton pump inhibitors (e.g. pantoprazole) or Type 2 histamine antagonists (e.g. cimetidine)
  • Diagnosis or treatment for another malignancy within 3 years of enrollment with the exception of complete resection of basal cell or squamous cell carcinoma of the skin, an in situ malignancy or low-risk prostate cancer after curative therapy
  • Inadequate bone marrow function
  • Abnormal liver function
  • Abnormal renal function
  • Abnormal coagulation

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Both
18 Years and older
No
Contact: For site information, send an email with site number to Contact-Us@sanofi.com
United States
 
NCT01410513
TCD12012, U1111-1119-2906
Not Provided
Sanofi
Sanofi
Not Provided
Study Director: Clinical Sciences & Operations Sanofi
Sanofi
July 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP